Ambit Expands Board, Names Execs

San Diego-based Ambit Biosciences, a developer of small molecule treatments for cancer, said today that it has named Faheem Hasnain as its Chairman of the board, added Alan Fuhrman as its Chief Financial Officer, and promoted Chritopher Morl to Chief Operating Officer. Hasnain was most recently President, CEO, and director of Facet Biotechnology, which was just acquired by Abbot Laboratories; he has also served at PDL Biopharma, Biogen Idec, and the Oncology Therapeutics Network. Fuhrman joins from Naviscan, where he was VP and CFO. Morl has been at Ambit since January 2009, and has previously served at Agensys, GlaxoSmithKline, and SmithKline Beecham.